Caris Life Sciences, Inc. (CAI): Valuation
TTM figures as of June 30, 2026
Caris Life Sciences, Inc. trades at 65.4 times trailing earnings and a 1.80% free-cash-flow yield. The Healthcare median P/E is 22.9.
Earnings yield 1.53%. Shareholder yield 0.31%. ROIC 17.4%. Net debt $290.5M.
15 month-end valuation observations are on file, starting June 2025.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is CAI cheap versus its own history?
Caris Life Sciences, Inc. trades at 65.4 times trailing earnings and a 1.80% free-cash-flow yield. The Healthcare median P/E is 22.9.
What is CAI's free-cash-flow yield?
Caris Life Sciences, Inc. currently yields 1.80% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.